Brief: Enlivex Announces Authorization From The Danish Regulatory Agency For Its Randomized, Controlled Phase I/II Trial
16/04/2024 13:38
April 16 (Reuters) - Enlivex Therapeutics Ltd ENLV.TA :
* ENLIVEX ANNOUNCES AUTHORIZATION FROM THE DANISH REGULATORY
AGENCY FOR THE COMPANY’S RANDOMIZED, CONTROLLED PHASE I/II TRIAL
EVALUATING ALLOCETRA IN PATIENTS WITH KNEE OSTEOARTHRITIS
* ENLIVEX ANNOUNCES AUTHORIZATION FROM THE DANISH REGULATORY
AGENCY FOR THE COMPANY’S RANDOMIZED, CONTROLLED PHASE I/II TRIAL
EVALUATING ALLOCETRA IN PATIENTS WITH KNEE OSTEOARTHRITIS
Source text for Eikon: ID:nGNX46kqJW
Further company coverage: ENLV.TA
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Enlivex
See all newsBrief: Enlivex Ltd Registers Up To 23,333,333 Ordinary Shares For Resale By Selling Shareholder
Brief: Enlivex Announces Second Regulatory Approval For Phase 2B Trial Of Allocetra In Age-Related Primary Moderate-To-Severe Knee Osteoarthritis
Brief: Enlivex Therapeutics Files For Offering Of Up To $299.6 Mln Of Ordinary Shares
Brief: Enlivex Announces Positive 6-Month Topline Data For Patients with Knee Osteoarthritis
Brief: Enlivex Files Patent for Allocetra Use in Osteoarthritis Treatment